Suppression of LNCaP prostate cancer xenograft tumors by a prostate-specific protein tyrosine phosphatase, prostatic acid phosphatase

Prostate

Volumn 55, Issue 4, 2003, Pages 247-258

  Igawa, Tsukasa ^a,b   Lin, Fen Fen ^a   Rao, Prathibha ^a   Lin, Ming Fong ^a,c  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b NAGASAKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

c ErbB 2; Intratumoral injection; LNCaP cells; PAcP; Prostate cancer; PTPase

Indexed keywords

ACID PHOSPHATASE PROSTATE ISOENZYME; ANDROGEN; COMPLEMENTARY DNA; CYCLINE; ONCOPROTEIN; PROSTATE SPECIFIC ANTIGEN; PROTEIN TYROSINE PHOSPHATASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CANCER MODEL; CARCINOGENICITY; CELL LINE; CONTROLLED STUDY; DEPHOSPHORYLATION; FEMALE; GENE THERAPY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE EPITHELIUM; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; WESTERN BLOTTING; XENOGRAFT;

ANIMALS; CELL DIVISION; DNA; FEMALE; GENE THERAPY; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASMS, HORMONE-DEPENDENT; PHOSPHORYLATION; PROLIFERATING CELL NUCLEAR ANTIGEN; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; PROTEIN-TYROSINE-PHOSPHATASE; RECEPTOR, EPIDERMAL GROWTH FACTOR; TRANSFECTION; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 0038136985     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/pros.10240     Document Type: Article

References (46)

1. Isaacs JT. The biology of hormone refractory prostate cancer. Why does it develop? Urol Clin North Am 1999;26:263-273.
2. Crawford ED, Rosenblum M, Ziada AM, Lange PH. Hormone refractory prostate cancer. Urology 1999;54:1-7.
3. Steiner MS, Gingrich JR. Gene therapy for prostate cancer: Where are we now? J Urol 2000;164:1121-1136.
4. Harrington KJ, Spitzweg C, Bateman AR, Morris JC, Vile RG. Gene therapy for prostate cancer: Current status and future prospects. J Urol 2001;166:1220-1233.
5. Morris MJ, Scher HI. Novel strategies and therapeutics for the treatment of prostate carcinoma. Cancer 2000;89:1329-1348.
6. Eastham JA, Hall SJ, Sehgal I, Wang J, Timme TL, Yang G, Connell-Crowley L, Elledge SJ, Zhang WW, Harper JW, Thompson TC. In vivo gene therapy with p53 or p21 adenovirus for prostate cancer. Cancer Res 1995;55:5151-5155.
7. Asgari K, Sesterhenn IA, McLeod DG, Cowan K, Moul JW, Seth P, Srivastava S. Inhibition of the growth of pre-established subcutaneous tumor nodules of human prostate cancer cells by single injection of the recombinant adenovirus p53 expression vector. Int J Cancer 1997;71:377-382.
8. Ogiso Y, Sakai N, Watari H, Yokoyama T, Kuzumaki N. Suppression of various human tumor cell lines by a dominant negative H-ras mutant. Gene Ther 1994;1:403-407.
9. Steiner MS, Anthony CT, Lu Y, Holt JT. Antisense c-myc retroviral vector suppresses established human prostate cancer. Hum Gene Ther 1998;9:747-755.
10. Eastham JA, Chen SH, Sehgal I, Yang G, Timme TL, Hall SJ, Woo SL, Thompson TC. Prostate cancer gene therapy: Herpes simplex virus thymidine kinase gene transduction followed by ganciclovir in mouse and human prostate cancer models. Hum Gene Ther 1996;7:515-523.
11. Hall SJ, Mutchnik SE, Yang G, Timme TL, Nasu Y, Bangma CH, Woo SL, Shaker M, Thompson TC. Cooperative therapeutic effects of androgen ablation and adenovirus-mediated herpes simplex virus thymidine kinase gene and ganciclovir therapy in experimental prostate cancer. Cancer Gene Ther 1999;6:54-63.
12. Wei C, Willis RA, Tilton BR, Looney RJ, Lord EM, Barth RK, Frelinger JG. Tissue-specific expression of the human prostate-specific antigen gene in transgenic mice: Implications for tolerance and immunotherapy. Proc Natl Acad Sci USA 1997;94:6369-6374.
13. Vihko P. Human prostatic acid phosphatases: Purification of a minor enzyme and comparisons of the enzymes. Invest Urol 1979;16:349-352.
14. Morris MF, Waheed A, Risley JM, Van Etten RL. Carbohydrate removal fails to eliminate the heterogeneity of human prostatic acid phosphatase. Clin Chim Acta 1989;182:9-20.
15. Oesterling JE. Prostate specific antigen: A critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J Urol 1991;145:907-923.
16. Bunting PS. Is there still a role for prostatic acid phosphatase? CSCC position statement. Canadian Society of Clinical Chemists. Clin Biochem 1999;32:591-594.
17. Denu JM, Stuckey JA, Saper MA, Dixon JE. Form and function in protein dephosphorylation. Cell 1996;87:361-364.
18. Li L, Dixon JE. Form, function, and regulation of protein tyrosine phosphatases and their involvement in human diseases. Semin Immunol 2000;12:75-84.
19. Lin MF, DaVolio J, Garcia-Arenas R. Expression of human prostatic acid phosphatase activity and the growth of prostate carcinoma cells. Cancer Res 1992;52:4600-4607.
20. Lin MF, Garcia-Arenas R, Chao YC, Lai MM, Patel PC, Xia XZ. Regulation of prostatic acid phosphatase expression and secretion by androgen in LNCaP human prostate carcinoma cells. Arch Biochem Biophys 1993;300:384-390.
21. Lin MF, Meng TC, Rao PS, Chang C, Schonthal AH, Lin FF. Expression of human prostatic acid phosphatase correlates with androgen-stimulated cell proliferation in prostate cancer cell lines. J Biol Chem 1998;273:5939-5947.
22. Meng TC, Lin MF. Tyrosine phosphorylation of c-ErbB-2 is regulated by the cellular form of prostatic acid phosphatase in human prostate cancer cells. J Biol Chem 1998;273:22096-22104.
23. Meng TC, Lee MS, Lin MF. Interaction between protein tyrosine phosphatase and protein tyrosine kinase is involved in androgen-promoted growth of human prostate cancer cells. Oncogene 2000;19:2664-2677.
24. Zhang XQ, Lee MS, Zelivianski S, Lin MF. Characterization of a prostate-specific tyrosine phosphatase by mutagenesis and expression in human prostate cancer cells. J Biol Chem 2001;276:2544-2550.
25. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A, Press MF. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989;244:707-712.
26. Strohmeyer TG, Slamon DJ. Proto-oncogenes and tumor suppressor genes in human urological malignancies. J Urol 1994;151:1479-1497.
27. Signoretti S, Montironi R, Manola J, Altimari A, Tam C, Bubley G, Balk S, Thomas G, Kaplan I, Hlatky L, Hahnfeldt P, Kantoff P, Loda M. Her-2-neu expression and progression toward androgen independence in human prostate cancer. J Natl Cancer Inst 2000;92:1918-1925.
28. Reese DM, Small EJ, Magrane G, Waldman FM, Chew K, Sudilovsky D. HER2 protein expression and gene amplification in androgen-independent prostate cancer. Am J Clin Pathol 2001;116:234-239.
29. Sakai H, Shiraishi K, Minami Y, Yushita Y, Kanetake H, Saito Y. Immunohistochemical prostatic acid phosphatase level as a prognostic factor of prostatic carcinoma. Prostate 1991;19:265-272.
30. Lin MF, Lee MS, Zhou XW, Andressen JC, Meng TC, Johansson SL, West WW, Taylor RJ, Anderson JR, Lin FF. Decreased expression of cellular prostatic acid phosphatase increases tumorigenicity of human prostate cancer cells. J Urol 2001;166:1943-1950.
31. Igawa T, Lin FF, Lee MS, Karan D, Batra SK, Lin MF. Establishment and characterization of androgen-independent human prostate cancer LNCaP cell model. Prostate 2002;50:222-235.
32. Egilmez NK, Iwanuma Y, Bankert RB. Evaluation and optimization of different cationic liposome formulations for in vivo gene transfer. Biochem Biophys Res Commun 1996;221:169-173.
33. Nomura T, Nakajima S, Kawabata K, Yamashita F, Takakura Y, Hashida M. Intratumoral pharmacokinetics and in vivo gene expression of naked plasmid DNA and its cationic liposome complexes after direct gene transfer. Cancer Res 1997;57:2681-2686.
34. Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang SI, Puc J, Miliaresis C, Rodgers L, McCombie R, Bigner SH, Giovanella BC, Ittmann M, Tycko B, Hibshoosh H, Wigler MH, Parsons R. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 1997;275:1943-1947.
35. Cheney IW, Johnson DE, Vaillancourt MT, Avanzini J, Morimoto A, Demers GW, Wills KN, Shabram PW, Bolen JB, Tavtigian SV, Bookstein R. Suppression of tumorigenicity of glioblastoma cells by adenovirus-mediated MMAC1/PTEN gene transfer. Cancer Res 1998;58:2331-2334.
36. Minaguchi T, Mori T, Kanamori Y, Matsushima M, Yoshikawa H, Taketani Y, Nakamura Y. Growth suppression of human ovarian cancer cells by adenovirus-mediated transfer of the PTEN gene. Cancer Res 1999;59:6063-6067.
37. Maehama T, Dixon JE. The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. J Biol Chem 1998;273:13375-13378.
38. Myers MP, Pass I, Batty IH, Van der Kaay J, Stolarov JP, Hemmings BA, Wigler MH, Downes CP, Tonks NK. The lipid phosphatase activity of PTEN is critical for its tumor supressor function. Proc Natl Acad Sci USA 1998;95:13513-13518.
39. Yamada KM, Araki M. Tumor suppressor PTEN: Modulator of cell signaling, growth, migration, and apoptosis. J Cell Sci 2001;114:2375-2382.
40. Kioschis P, Rogner UC, Pick E, Klauck SM, Heiss N, Siebenhaar R, Korn B, Coy JF, Laporte J, Liechti-Gallati, S, Poustka A. A 900-kb cosmid contig and 10 new transcripts within the candidate region for myotubular myopathy (MTM1). Genomics 1996;33:365-373.
41. Minassian BA, Sainz J, Serratosa JM, Gee M, Sakamoto LM, Bohlega S, Geoffroy G, Barr C, Scherer SW, Tomiyasu U, Carpenter S, Wigg K, Sanghvi AV, Delgado-Escueta AV. Genetic locus heterogeneity in Lafora's progressive myoclonus epilepsy. Ann Neurol 1999;45:262-265.
42. McNeel DG, Nguyen LD, Disis ML. Identification of T helper epitopes from prostatic acid phosphatase. Cancer Res 2001;61:5161-5167.
43. Inoue Y, Takaue Y, Takei M, Kato K, Kanai S, Harada Y, Tobisu K, Noguchi M, Kakizoe T, Itoh K, Wakasugi H. Induction of tumor specific cytotoxic T lymphocytes in prostate cancer using prostatic acid phosphatase derived HLA-A2402 binding peptide. J Urol 2001;166:1508-1513.
44. Zelivianski S, Larson C, Seberger J, Taylor R, Lin M. Expression of human prostatic acid phosphatase gene is regulated by upstream negative and positive elements. Biochim Biophys Acta 2000;1491:123-132.
45. Zelivianski S, Igawa T, Lim S, Taylor R, Lin MF. Identification and characterization of regulatory elements of the human prostatic acid phosphatase promoter. Oncogene 2002;21:3696-3705.
46. Chu TM, Lin MF. PSA and acid phosphatase in the diagnosis of prostate cancer. J Clin Ligand Assay 1998;21:24-34.